Related Experiment Videos
Interleukin-6 polymorphism is associated with more aggressive prostate cancer
Dongfeng Tan1, Xiuxian Wu, Min Hou
1Department of Pathology, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
The Journal of Urology
|July 12, 2005
Summary
The -174G>C polymorphism in the Interleukin-6 (IL-6) gene is linked to increased risk and aggressiveness of prostate cancer. This genetic variation is associated with advanced disease, higher Gleason scores, and cancer recurrence.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) plays a key role in prostate cancer progression.
- Elevated serum IL-6 levels are observed in advanced and hormone-refractory prostate cancer.
- The -174G>C polymorphism in the IL-6 gene promoter influences IL-6 transcription and protein levels.
Purpose of the Study:
- To investigate the association between the IL-6 -174G>C polymorphism and prostate cancer progression.
- To determine if this genetic variation correlates with advanced disease stages and clinical outcomes.
Main Methods:
- Utilized tetra-primer polymerase chain reaction (PCR) genotyping.
- Analyzed 95 prostate cancer patients with varying disease stages.
- Examined the association of IL-6 polymorphism with clinicopathological features.
Main Results:
- The -174G>C genotype was associated with an increased risk of advanced prostate cancer.
- Significant links were found between this genotype and Gleason score, tumor stage (T3-T4 vs. T1-T2), vascular invasion, seminal vesicle involvement, and capsular invasion.
- The genotype correlated with elevated serum prostate-specific antigen (PSA) and a higher risk of cancer recurrence.
Conclusions:
- The -174G>C polymorphism of the IL-6 gene is strongly associated with prostate cancer aggressiveness and recurrence.
- Genetic predisposition due to IL-6 gene variations may influence the risk of recurrent prostate cancer.